/cloudfront-us-east-1.images.arcpublishing.com/morningstar/KD4XZLC72BDERAS3VXD6QM5MUY.png)
Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/OBA7UVI75RGFDOHGJTZ2FK542Q.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/JNGGL2QVKFA43PRVR44O6RYGEM.png)
Latest Company Reports
- CVACCureVac NV Ordinary Shares
CureVac Continues to Burn Cash; Provides Very Risk-Tolerant Investors With Exposure to mRNA Pipeline
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
- Rating
- Price
- $3.13
- Fair Value
- $4.63
- Uncertainty
- Extreme
- Economic Moat
- Scj
- Capital Allocation
- Mxjglczzq
- PHGKoninklijke Philips NV ADR
Philips' Settlement Removes Some Uncertainty
- Rating
- Price
- $26.24
- Fair Value
- $82.43
- Uncertainty
- High
- Economic Moat
- Kxdwm
- Capital Allocation
- Vmskngrq
- CRONCronos Group Inc
Cronos Is Unlikely to Generate Positive Adjusted EBITDA for the Foreseeable Future
/s3.amazonaws.com/arc-authors/morningstar/220f0649-85f9-4004-a281-b91d9bc53139.jpg)
- Rating
- Price
- $2.25
- Fair Value
- $7.20
- Uncertainty
- Very High
- Economic Moat
- Cbfmx
- Capital Allocation
- Tfyrxqs
- CGCCanopy Growth Corp
US Deals Help Unlock Some Value but Doesn't Help Canopy Growth's Lagging Canadian Operations
- Rating
- Price
- $6.26
- Fair Value
- $7.10
- Uncertainty
- Extreme
- Economic Moat
- Cjkx
- Capital Allocation
- Gwjd
- WBAWalgreens Boots Alliance Inc
Walgreens' Recovery Looks Uncertain as Retail Continues to Suffer and More Store Closures Underway
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
- Rating
- Price
- $10.82
- Fair Value
- $13.00
- Uncertainty
- Very High
- Economic Moat
- Cjb
- Capital Allocation
- Ldxy
- TLRYTilray Brands Inc
Tilray's Mixed Portfolio Unlikely to Yield Synergies as Canadian Market Remains a Major Challenge
- Rating
- Price
- $1.75
- Fair Value
- $8.00
- Uncertainty
- Very High
- Economic Moat
- Wzqc
- Capital Allocation
- Vddzdpph
- ACBAurora Cannabis Inc
Aurora's Debt Load Severely Reduced, but Its Small Size Will Hinder Investment Ability and Growth
- Rating
- Price
- $4.95
- Fair Value
- $9.40
- Uncertainty
- Extreme
- Economic Moat
- Nxlxk
- Capital Allocation
- Cghp
- ILMNIllumina Inc
Illumina Spins Off Grail to Shareholders
/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
- Rating
- Price
- $107.84
- Fair Value
- $427.00
- Uncertainty
- High
- Economic Moat
- Jjghx
- Capital Allocation
- Nhnjlxcmy
- ALNYAlnylam Pharmaceuticals Inc
Narrow-Moat Alnylam's Positive Data in Vutrisiran ATTR-CM Trial Should Drive Strong Long-Term Growth
- Rating
- Price
- $255.11
- Fair Value
- $286.00
- Uncertainty
- High
- Economic Moat
- Qkqbl
- Capital Allocation
- Hxgjtkdvr
- CURLFCuraleaf Holdings Inc
Curaleaf Positioned for Long-Term Growth From US and International Market Tailwinds
- Rating
- Price
- $3.91
- Fair Value
- $66.00
- Uncertainty
- Very High
- Economic Moat
- Zyzd
- Capital Allocation
- Hyzlmxrk
- GTBIFGreen Thumb Industries Inc
Green Thumb's Growth Should Benefit From Easing Federal Prohibition and New State Legalizations
- Rating
- Price
- $11.80
- Fair Value
- $27.00
- Uncertainty
- Very High
- Economic Moat
- Qjgp
- Capital Allocation
- Zrvfwslzw
- LHLabcorp Holdings Inc
LabCorp Can Prioritize Diagnostics Now Without Distractions
/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)
- Rating
- Price
- $202.96
- Fair Value
- $674.18
- Uncertainty
- Medium
- Economic Moat
- Bymrdx
- Capital Allocation
- Zdzmrhddd
- QGENQiagen NV
Qiagen Still Pushing for Higher Growth Than Its End Markets
- Rating
- Price
- $40.24
- Fair Value
- $83.00
- Uncertainty
- Medium
- Economic Moat
- Gfqr
- Capital Allocation
- Hflpptkm
- TFXTeleflex Inc
Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
- Rating
- Price
- $211.73
- Fair Value
- $156.00
- Uncertainty
- Medium
- Economic Moat
- Wcj
- Capital Allocation
- Rmbhw
- ATRAptarGroup Inc
Aptar's Profitability Improving Due to Pharma Growth and Cost Controls
- Rating
- Price
- $141.51
- Fair Value
- $421.00
- Uncertainty
- Medium
- Economic Moat
- Qrvvlq
- Capital Allocation
- Vghdxxr
Largest Stocks in the Healthcare Sector
|
1-Day Chart
|
Name
|
Industry
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Drug Manufacturers - General | Gphwzswgj | Tqkk | $826.6 Bil | |||
| Novo Nordisk A/S ADR
NVO
| Biotechnology | Frtvnwvvc | Vbl | $636.3 Bil | |||
| UnitedHealth Group Inc
UNH
| Healthcare Plans | Mhwydhhff | Pggfrk | $450.4 Bil | |||
| Johnson & Johnson
JNJ
| Drug Manufacturers - General | Wvjrmnsnz | Qxx | $350.1 Bil | |||
| Merck & Co Inc
MRK
| Drug Manufacturers - General | Wlsfrbhw | Wdnvc | $318.6 Bil | |||
| AbbVie Inc
ABBV
| Drug Manufacturers - General | Cdrcynx | Ffgx | $294.1 Bil | |||
| AstraZeneca PLC ADR
AZN
| Drug Manufacturers - General | Twjjmtlf | Kzdm | $239.1 Bil | |||
| Novartis AG ADR
NVS
| Drug Manufacturers - General | Csmnqggc | Ywvx | $221.6 Bil | |||
| Thermo Fisher Scientific Inc
TMO
| Diagnostics & Research | Mmmkybyjt | Crgh | $204.7 Bil | |||
| Danaher Corp
DHR
| Diagnostics & Research | Bmmvphrj | Gqmqqz | $178.2 Bil |
More in Healthcare
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/RFJBWBYYTARXBNOTU6VL4VSE4Q.png)
19 Best Healthcare Companies to Invest In
These companies largely earn their competitive advantage from intangible assets, and their stocks are great choices for an investor’s watchlist.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/KD4XZLC72BDERAS3VXD6QM5MUY.png)
Healthcare Stocks: Valuations Look Attractive Across Almost All Industries
Our top picks in the sector are Illumina, Moderna, and Zimmer Biomet.
Healthcare: Valuations Look Attractive Across Almost All Industries
We think the best healthcare stocks include Illumina, Moderna, and Zimmer Biomet.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/HDPMMDGUA5CUHI254MRUHYEFWU.png)
3 Gold-Rated Funds Whose Managers Love Healthcare Stocks
Although the sector has suffered recently, it won’t hurt these well-run funds forever.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/22DGCGOHMJC7HHQIF2CERYV4JM.png)
Healthcare: Valuations Look Attractive Across Most Industries
We view the sector as undervalued, as the market is not fully appreciating its innovations.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/7B2BNWABPGQEALZ7BNPW5JW3PM.jpg)
A Checklist for Open Enrollment Season
If you’re signing up for employer-provided benefits, don’t just re-up for last year’s choices.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/L644DYLVFJDCLOIAOSBZUGFIEU.png)
8 Undervalued Quality Healthcare Stocks
These wide-moat healthcare stocks are trading below their fair value estimates.
Healthcare Stock Outlook: Innovative Products and Defensive Nature Should Support Solid Results in Uncertain Times
We see plenty of opportunities in healthcare, especially in biopharma, healthcare providers, healthcare plans, and diagnostics and research.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/4TYZEEXD3RGWNKTVNUJBWDUFAM.jpg)
Is UnitedHealth Stock a Buy, Sell, or Fairly Valued After Earnings?
Here’s what we think of UnitedHealth stock as surging demand for healthcare could strain near-term margins.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/66O6YFGQPK4B3UEPMKAPFPKPOA.png)
2 Undervalued Medtech Stocks: Opportunities in Liquid Biopsy
Liquid biopsies could usher in a paradigm shift in cancer detection and grow exponentially.